Recent Blog Posts

View Post: Celator Pharmaceuticals Presents Data on the Activity of CPX-351 ...
9 Jun 2009
Harasym T, Lim W, Tardi P, et al. Leukemia cell-selective uptake of cytarabine (Cyt) and daunorubicin (Daun) mediated by CPX-351 liposome injection in the bone marrow compartment. EHA Abstract #383. Source: Celator Pharmaceuticals, Inc. ...
View Blog: Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html

---

View Post: Orphan drug designation granted to voreloxin for acute myeloid ...
5 Nov 2009
September 10, 2009. Centocor Ortho Biotech Products (a division of Johnson & Johnson) announced that it received a complete response letter from the FDA regarding the New Drug Application (NDA) for trabectedin in combination with Doxil ( doxorubicin HCI liposome injection) for the treatment of relapsed ovarian cancer. ... Neoplasms > Cytotoxic antibiotics. Daunorubicin HCl 20mg/vial; lyophilized pwd for IV infusion after reconstitution; contains mannitol. ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Celator Pharmaceuticals Announces Enrollment of First Patient in ...
18 Nov 2008 by admin  
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML) ...
View Blog: BreakThrough Digest Medical News - http://www.breakthroughdigest.com/

---

View Post: celator(r) pharmaceuticals presents phase 1 results with cpx-351 ...
9 Aug 2009 by sebeliusmany  
celator pharmaceuticals announced that a phase 1 dose escalating study of cpx-351 (cytarabine:daunorubicin) liposome injection established the recommended dosage for taper off 2 studies and confirmed preliminary observations of safety, ...
View Blog: Sebelius many - http://blog.flugur.is/sebeliusmany/

---

View Post: celator(r) pharmaceuticals presents new data on cpx-351 and cpx-1 ...
18 Jul 2009 by untilpoor  
celator pharmaceuticals announced that chic data from gross studies of cpx-351 (cytarabine:daunorubicin) liposome injection in consolidation treatment for leukemia and of cpx-1 (irinotecan hcl:floxuridine) liposome injection in ...
View Blog: Until poor - http://untilpoor.blog.migranci.pl/

---

View Post: Jump Into The Cloud
SlideRocket Online Presentation Software
5 May 2008 by nat   ...
View Blog: http://www.sliderocket.com/blog/

---

View Post: The Leukemia & Lymphoma Society and Celator Pharmaceuticals ...
22 Jan 2009
... Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). ...
View Blog: Latest Medical Technology from Bio-Medicine.Org - http://www.bio-medicine.org/medicine-technology-1/

---

View Post: Celator(R) Pharmaceuticals Completes Enrollment Early In Phase 2 ...
13 Oct 2009 by Pharma Industry / Biotech Industry News...  
Celator Pharmaceuticals announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin ...
View Blog: PharmaCompanies.info - http://www.farmanux.com/wpnews/

---

View Post: Cancer Information Online: Secondary lung cancer
8 Jun 2007 by Xincon  
You will usually be given an injection of a liquid that enables the pictures to be seen more clearly. The test can take up to an hour and is completely painless. If you don't like enclosed spaces you may find the machine claustrophobic. ...
View Blog: Cancer Information Online - http://online-cancer-information.blogspot.com/

---

View Post: A Review on PEGylated Liposome in Cancer Therapy and in Delivery ...
13 Nov 2007
Anti-cancer drugs such as Doxorubicin (Doxil) and Daunorubicin (Daunoxome) are currently being marketed in liposome delivery systems.The use of liposomes for transformation or transfection of DNA into a host cell is known as lipofection. ..... After two weeks of tail intravenous injection of the pegylated liposomal doxorubicin at a single dose of 10 mg/kg, no significant damage was observed in gastric, intestinal mucosa, and heart muscle, but pronounced damages were found ...
View Blog: Pharmainfo.net - Latest Reviews - http://www.pharmainfo.net/taxonomy/term/1760/0

---